Welcome to our dedicated page for Ethos Technologies news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on Ethos Technologies stock.
Ethos Technologies Inc. reports developments tied to its digital life insurance platform, which connects consumers, independent agents and insurance carriers through online underwriting and policy issuance tools. The company distributes life insurance products in direct-to-consumer and third-party channels and earns carrier commissions and administrator-service revenue from activated policies.
Recurring updates include quarterly results, direct and third-party channel revenue, policy activation trends, and technology integrations that expand digital purchasing. Company announcements also cover carrier collaborations and product additions, including whole life, final expense, and indexed universal life offerings delivered through Ethos' platform.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced significant progress in its clinical trials for ATYR1923 aimed at treating pulmonary sarcoidosis, with results from a Phase 1b/2a trial expected by mid-September 2021.
The company confirmed the completion of patient visits and showcased a positive safety profile for ATYR1923 in preliminary studies. Additionally, they reported second-quarter 2021 financials, with cash reserves of $44.1 million and R&D expenses at $7.7 million, reflecting ongoing investment in innovative therapies.
aTyr Pharma, Inc. (Nasdaq: LIFE) has expanded its research collaboration with The Ohio State University to explore immune mechanisms and identify biomarkers of efficacy for its lead therapy, ATYR1923, targeting pulmonary sarcoidosis. Led by Dr. Elliott Crouser, the collaboration aims to analyze blood samples from sarcoidosis patients to understand granuloma formation and potentially improve treatment outcomes. Given that existing treatments offer limited efficacy, this study may significantly impact patient management. The findings from a related pilot study will be presented at the upcoming European Respiratory Society Congress.
On August 9, 2021, aTyr Pharma (Nasdaq: LIFE) announced the acceptance of two abstracts for its lead candidate, ATYR1923, at the 2021 European Respiratory Society Congress, scheduled online from September 5-8. The first abstract discusses ATYR1923's role in reducing biomarkers in COVID-19 pneumonia, while the second focuses on its inhibition of sarcoid granuloma formation. aTyr is developing ATYR1923 for severe inflammatory lung diseases and has completed enrollment in a Phase 1b/2a trial for pulmonary sarcoidosis, with a recent Phase 2 trial showing promising results in COVID-19 patients.
aTyr Pharma (Nasdaq: LIFE) announced on August 3, 2021, that it will report its second quarter 2021 financial results and provide a corporate update on August 10, 2021, after the market closes. A conference call and webcast are scheduled for the same day at 5:00 PM EDT. The company focuses on developing innovative medicines based on novel biological pathways, particularly their clinical-stage product candidate, ATYR1923, aimed at treating inflammatory lung diseases.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced that the U.S. Patent and Trademark Office has granted a patent for methods using histidyl-tRNA synthetase Fc fusion proteins to reduce inflammatory responses in the lung. This patent pertains to ATYR1923, a candidate in clinical development for pulmonary sarcoidosis and other inflammatory lung diseases. The patent expands aTyr's intellectual property estate, which includes over 220 patents. Results from recent trials show that ATYR1923 may effectively lower inflammatory cytokine levels in patients.
aTyr Pharma (Nasdaq: LIFE) announced that the last patient in its Phase 1b/2a clinical trial of ATYR1923 for pulmonary sarcoidosis has completed their final visit. The trial, involving 37 patients, aims to assess the safety, tolerability, and preliminary efficacy of ATYR1923. Results are anticipated in September 2021. ATYR1923, a fusion protein targeting neuropilin-2, seeks to modulate immune responses in severe inflammatory lung diseases. This milestone is a significant step for aTyr and the sarcoidosis community.
aTyr Pharma, Inc. (Nasdaq: LIFE) will host a virtual Key Opinion Leader event on June 29, 2021, at 5:00 PM ET, featuring Dr. Daniel Culver from the Cleveland Clinic. The discussion will focus on treatment options for pulmonary sarcoidosis, addressing the unmet needs of patients and the challenges of long-term steroid use. aTyr’s lead candidate, ATYR1923, is under evaluation in a Phase 1b/2a study for its safety and efficacy, with data expected in Q3 2021. Attendees will also have the opportunity to engage in a live Q&A session.
aTyr Pharma announced the presentation of its preclinical candidate aNRP2-14 at the Antibody Engineering & Therapeutics Europe Virtual conference, which took place from June 8 to 10, 2021. This antibody selectively blocks Semaphorin 3F/NRP2 signaling pathways linked to immune-mediated diseases, demonstrating significant potential. The findings suggest that aNRP2-14 could serve a therapeutic role, expanding aTyr's pipeline targeting chronic inflammation. This follows the development of their lead candidate, ATYR2810, which is in preclinical trials for cancer.
aTyr Pharma (Nasdaq: LIFE) has appointed Dr. Sara Zaknoen to its Board of Directors. Dr. Zaknoen, with extensive experience in pharmaceutical drug development, previously served as Chief Medical Officer at several biotech firms. This strategic appointment comes as aTyr prepares for the readout of its proof-of-concept study for ATYR1923 in pulmonary sarcoidosis by Q3 2021. The company is also advancing its oncology candidate ATYR2810, targeting Neuropilin-2. Dr. Zaknoen's background is expected to enhance aTyr's clinical development efforts.
aTyr Pharma announced findings related to ATYR2810, a Neuropilin-2 (NRP2) antibody, presented at the Virtual Keystone Symposia on Cancer Stem Cells. The research demonstrates that ATYR2810 effectively blocks the NRP2/VEGF signaling axis, enhancing chemotherapy sensitivity in triple-negative breast cancer (TNBC) models. Notably, ATYR2810 downregulates cancer stem cell and epithelial-mesenchymal transition markers in TNBC samples. These findings underscore the potential of ATYR2810 as a therapeutic candidate in treating aggressive tumors.